<DOC>
	<DOCNO>NCT01820260</DOCNO>
	<brief_summary>To identify Maximum Tolerated Dose level ingenol mebutate gel daily treatment 2 3 consecutive day evaluate efficacy ingenol mebutate gel different dos daily treatment 2 3 consecutive day compare vehicle gel</brief_summary>
	<brief_title>Safety Efficacy Doses Ingenol Mebutate Once Daily Two Three Consecutive Days Subjects With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subjects must competent understand nature trial provide inform consent Part 1 : Subjects 5 20 clinically typical , visible discrete AKs face Part 2 : Subjects 5 20 clinically typical , visible discrete AKs either face , bald scalp ( bald part scalp least 25 cm2 ) contiguous area approximately 250 cm2 chest Subject least 18 year age Female subject must either : 1 . Nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus ) , 2 . Childbearing potential , provide confirm negative urine pregnancy test prior trial treatment , rule pregnancy Female subject childbearing potential1 must willing use effective contraception trial entry completion Location treatment area ( full face , full balding scalp chest ) within 5 cm incompletely heal wound , within 10 cm suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC Prior treatment ingenol mebutate gel within treatment area Lesions treatment area : atypical clinical appearance ( e.g. , hypertrophic , hyperkeratotic cutaneous horn ) and/or , recalcitrant disease ( e.g. , respond cryotherapy two previous occasion History evidence skin condition trial indication would interfere evaluation trial medication ( e.g. , eczema , unstable psoriasis , xeroderma pigmentosum ) Use cosmetic therapeutic product procedure could interfere assessment treatment area . Clinical diagnosis/history evidence medical condition would expose subject undue risk significant AE interfere assessment safety efficacy course trial , determine investigator 's clinical judgment Any abnormal laboratory test medically significant would impact safety subject interpretation trial result , determine investigator 's judgment Anticipated need hospitalisation outpatient surgery first 15 day first trial medication application . Note cosmetic/therapeutic procedure exclude fall outside criterion detail Prohibited Therapies Medications Known sensitivity allergy ingredient ingenol mebutate gel Presence acute sunburn within treatment area Current enrolment participation investigational clinical trial within 30 day entry trial . Subjects previously assign treatment Part 1 rand Female subject breastfeed . In opinion investigator , subject unlikely comply Clinical Study Protocol ( e.g . alcoholism , drug dependency psychotic state )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>